期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 56, 期 13, 页码 1001-1012出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.03.083
关键词
calcium channel blockers; chelation; hemochromatosis; hemosiderosis; iron overload cardiomyopathy; T2*MRI
资金
- NHLBI/NIH
The prevalence of iron overload cardiomyopathy (IOC) is increasing. The spectrum of symptoms of IOC is varied. Early in the disease process, patients may be asymptomatic, whereas severely overloaded patients can have terminal heart failure complaints that are refractory to treatment. It has been shown that early recognition and intervention may alter outcomes. Biochemical markers and tissue biopsy, which have traditionally been used to diagnose and guide therapy, are not sensitive enough to detect early cardiac iron deposition. Newer diagnostic modalities such as magnetic resonance imaging are noninvasive and can assess quantitative cardiac iron load. Phlebotomy and chelating drugs are suboptimal means of treating IOC; hence, the roles of gene therapy, hepcidin, and calcium channel blockers are being actively investigated. There is a need for the development of clinical guidelines in order to improve the management of this emerging complex disease. (J Am Coll Cardiol 2010; 56: 1001-12) (C) 2010 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据